P. E. Fisher

Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects.

M. Wachsman, H. Jaffe, P. Lietman, 1996, Antiviral research.

The ShiA protein encoded by the Shigella flexneri SHI‐2 pathogenicity island attenuates inflammation

E. Groisman, A. Zychlinsky, M. Ingersoll, 2003, Cellular microbiology.

Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria

R. Davey, J. Kovacs, M. Polis, 1995, Antimicrobial agents and chemotherapy.

Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS.

W. Owen, S. Safrin, J. Lalezari, 1994, The Journal of infectious diseases.

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue.

J. C. Martin, J. Hannigan, J. Lalezari, 1995, The Journal of infectious diseases.

Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients

M. Polis, M. Wachsman, J. Lalezari, 1995, Antimicrobial agents and chemotherapy.

Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial.

F. Lewis, T. Clemmer, D. Trunkey, 1994, Archives of surgery.